FibroBiologics, Inc. (FBLG)
NASDAQ: FBLG · Real-Time Price · USD
1.215
-0.075 (-5.81%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Company Description
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company.
It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials.
The company was founded in 2021 and is based in Houston, Texas.
FibroBiologics, Inc.
| Country | United States |
| Founded | 2021 |
| IPO Date | Jan 31, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Peter O’Heeron |
Contact Details
Address: 455 East Medical Center Boulevard, Suite 300 Houston, Texas 77598 United States | |
| Phone | 281-651-5150 |
| Website | fibrobiologics.com |
Stock Details
| Ticker Symbol | FBLG |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $30.00 |
| CIK Code | 0001958777 |
| CUSIP Number | 31573L105 |
| ISIN Number | US31573L1052 |
| Employer ID | 86-3329066 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Peter O'Heeron | Founder, Chairperson and Chief Executive Officer |
| Dr. Hamid Khoja Ph.D. | Chief Scientific Officer |
| Ruben A. Garcia J.D. | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | ARS | Filing |
| Apr 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 11, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 31, 2025 | 10-K | Annual Report |
| Feb 12, 2025 | SCHEDULE 13G | Filing |
| Feb 10, 2025 | EFFECT | Notice of Effectiveness |
| Feb 7, 2025 | 8-K | Current Report |
| Feb 6, 2025 | UPLOAD | Filing |
| Feb 3, 2025 | S-3 | Registration statement under Securities Act of 1933 |